ONeil Trader
Articles
BioCryst Pharmaceuticals: BCX7353 Phase 3 Results To Make Or Break This Story
Why Amarin Is Stuck In A Trading Range
Horizon Pharma: Teprotumumab To Become A Key Commercial Asset In The 2020s
Axsome Therapeutics: AXS-05's Potential In Nicotine Addiction
Amicus Therapeutics: Looking A Few Years Ahead
A Tough Road Ahead For Neos Therapeutics
Achillion Pharmaceuticals: The Promise Of Alternative Pathway Inhibition
Ascendis Pharma's TransCon hGH Works Better Than Investors Expected
argenx: The Future Leader In The Autoimmune And Oncology Markets
Quotient Limited: MosaiQ's Approval And Launch A Few Months Away
Keeping Focused Amidst The Biotech Bear
Amarin: Addressing The Mineral Oil Issue
Amarin: More Room To Run After REDUCE-IT Success
Ra Pharmaceuticals: Is Trying To Copy What Works A Good Product Development Strategy?
Heron Therapeutics: Update After HTX-011 Nerve Block Results
Baozun Continues To Execute
Supernus Keeps Delivering
Learning From The Best - How Joseph Edelman (Perceptive Advisors) Invests
The Investment Case For InflaRx
NovoCure: 2018 Off To A Strong Start For Optune
Heron Therapeutics: Clear Path To Approval For HTX-011
ChemoCentryx: Significant Progress In Recent Months
More Positive Developments For Neurocrine
TG Therapeutics: The Most Important Catalyst Coming In Q2
LGI Homes: Growth To Slow Down In 2018
Amicus Therapeutics: What To Expect In 2018
Neos Therapeutics: Cotempla Off To A Strong Start
Omeros: OMS721 Updates Are Very Positive, But Where's The Update On Omidria?
Biotech: The Tide Is Turning
Global Blood Therapeutics: The Significance Of ASH Updates
Horizon Pharma: Primary Care Segment Remains A Burden And Should Be Sold
The Investment Case For Ascendis Pharma